Efficacy of acotiamide for scleroderma patients with esophageal symptoms

Efficacy of acotiamide for scleroderma patients with esophageal symptoms - Efficacy of acotiamide for scleroderma patients with esophageal symptoms.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031901

Enrollment

Registered

2018-03-26

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic sclerosis

Interventions

proton pump inhibitor proton pump inhibitor and acotiamide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the ACR/EULAR criteria for systemic sclerosis (2013) Patients who have esophageal symptoms (modified F scale of 8 or more)

Exclusion criteria

Exclusion criteria: Patients who have gastric ulcer and duodenal ulcer (excluding reflux esophagitis)

Design outcomes

Primary

Measure	Time frame
improvement of modified F scale	—

Secondary

Measure	Time frame
improvement of Izumo scale	—

Countries

Japan

Contacts

Public ContactKurisu Tada

Juntendo University School of Medicine Department of Internal Medicine and Rheumatology

chris@juntendo.ac.jp81-3-5802-1067

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026